Roche
NEWS
The U.S. Food and Drug Administration (FDA) accepted Merck’s new supplemental Biologics License Application (sBLA) for Keytruda.
Roche announced that its Phase III IMpower 133 clinical trial of Tecentriq (atezolizumab) plus carboplatin and etoposide chemotherapy met its co-primary endpoints.
There is another change coming to the senior leadership team at Swiss pharma giant Roche.
Three years after acquiring a majority stake Foundation Medicine, Pharma giant Roche has agreed to buy up all outstanding shares for about $2.4 billion and bring the company’s sequencing diagnostics platform under the Roche umbrella.
PTC Therapeutics presented updated interim clinical data from Part 1 of its FIREFISH clinical trial of risdiplam (RG7916) in babies with Type 1 Spinal Muscular Atrophy.
AbbVie and the Keck Graduate Institute (KGI) School of Pharmacy have partnered to form the first AbbVie-KGI Biopharmaceutical Industry Fellowship.
The U.S. Food and Drug Administration (FDA) recently reprimanded AbbVie for its processes for investigating reports of deaths associated with three of its drugs.
The U.S. Food and Drug Administration (FDA) approved AbbVie and Roche’s combination of Venclexta in combination with Rituxan (rituximab) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion in patients who have received at least one previous therapy.
The U.S. Food and Drug Administration (FDA) granted Genentech’s Tecentriq triple combination with Avastain (bevacizumab), paclitaxel and carboplatin (chemotherapy) Priority Review for first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
JOBS
IN THE PRESS